Scleroderma is a group of disorders in which inflammation and excessive collagen lead to fibrosis, making affected skin or other tissues unusually hard, thick or tight. The fibrotic tissue is less flexible than normal tissue, so visible skin change can be accompanied by stiffness, reduced movement, vascular problems or other symptoms depending on the disease type.
The first clinical distinction is whether the disease is localized scleroderma—most often morphea, which affects skin and sometimes deeper nearby tissues—or systemic sclerosis, an autoimmune disease that can also involve blood vessels and internal organs. Treatment therefore depends on the manifestation being treated, and systemic sclerosis requires ongoing organ monitoring even when the skin appears stable.
This article is for educational purposes only. Progressive skin tightening, fingertip ulcers, new breathing problems, sudden blood-pressure changes or other possible systemic symptoms should be professionally evaluated.
What Is Scleroderma and Why Does the Skin Become Hard and Tight?
Scleroderma causes hardened or tight tissue because abnormal immune and vascular activity can activate fibroblasts, leading to excessive collagen deposition and fibrosis.
How Does Excess Collagen Cause Fibrosis?
Excessive collagen accumulation makes affected tissue thicker, firmer and less flexible as normal tissue architecture is altered by fibrotic repair.
In systemic sclerosis, the process is commonly described as interacting immune dysregulation, blood-vessel injury and fibroblast activation. Fibroblasts then produce excess collagen and other extracellular-matrix proteins, which accumulate in skin and, in systemic disease, may also affect internal organs.
Is Scleroderma an Autoimmune Disease?
Systemic sclerosis is an autoimmune connective-tissue disease involving immune abnormalities, vascular dysfunction and fibrosis, although the event that first triggers the disease remains uncertain.
The broader word “scleroderma” also includes localized disease. That distinction matters because localized forms can extend into nearby fat, fascia, muscle or bone without producing the characteristic internal-organ vasculopathy and fibrosis of systemic sclerosis.
What Does Scleroderma Look and Feel Like on the Skin?
Scleroderma can cause puffy fingers, progressively tight or shiny skin, reduced flexibility, pigment change, dryness, itching and difficulty bending affected joints.
Fibrotic skin may feel firm or bound down and lose normal folds. Hair and sweating can decrease within involved areas, and tightening around the fingers, hands, mouth or joints can become functionally important rather than being only a cosmetic change.
What Are Sclerodactyly, Telangiectasia and Calcinosis?
Sclerodactyly describes tightened fibrotic skin of the fingers, telangiectasia refers to visible small dilated blood vessels, and calcinosis refers to calcium deposits in or beneath the skin.
These findings do not all appear in every person, but they help describe the pattern of systemic sclerosis when interpreted together with Raynaud phenomenon, digital ulcers, skin distribution and organ findings.
Figure 1. Scleroderma fibrosis reflects more than “extra collagen” alone: immune and vascular abnormalities can activate fibroblasts, producing collagen-rich tissue that becomes tight and functionally restrictive.
What Types of Scleroderma Affect the Skin and Internal Organs?
The most important distinction is between localized scleroderma, which affects skin and sometimes deeper nearby tissues, and systemic sclerosis, which also carries vascular and internal-organ risk.
What Is Localized Scleroderma or Morphea?
Localized scleroderma causes fibrotic patches or bands in the skin and can extend into nearby fat, fascia, muscle or bone, but it does not produce the characteristic internal-organ fibrosis or vascular injury of systemic sclerosis. The dedicated morphea page covers localized patterns such as plaque, linear and deeper disease in more detail.
Because depth matters, “localized” should not be read as “always superficial.” Linear or deep morphea can affect growth, joints or movement even though the disease remains different from systemic sclerosis.
What Is Systemic Sclerosis?
Systemic sclerosis combines autoimmunity, blood-vessel abnormalities and fibrosis and may affect both the skin and internal organs.
Possible complications include interstitial lung disease, pulmonary arterial hypertension, esophageal and other gastrointestinal dysfunction, cardiac disease, digital ischemia and kidney involvement. Not every person develops every manifestation, which is why baseline assessment and follow-up are individualized.
What Is the Difference Between Limited and Diffuse Systemic Sclerosis?
Limited cutaneous systemic sclerosis generally has skin involvement distal to the elbows and knees, often including the hands and face, while diffuse cutaneous disease extends more proximally onto the upper arms, thighs or trunk.
“Limited” describes the skin distribution; it does not mean harmless disease. People with limited cutaneous systemic sclerosis can still develop important pulmonary vascular, lung, gastrointestinal and other internal-organ complications, while diffuse disease tends to carry a different timing and pattern of organ risk.
How Can Raynaud Phenomenon Be an Early Systemic-Sclerosis Sign?
Raynaud phenomenon can precede other systemic-sclerosis signs and causes recurrent cold- or stress-triggered finger color changes from temporary narrowing of small blood vessels.
Raynaud is common and often occurs without systemic sclerosis, so it is not diagnostic by itself. Suspicion rises when Raynaud accompanies puffy fingers, fingertip ulcers, abnormal nailfold capillaries, skin tightening or disease-associated autoantibodies.
Figure 2. Localized scleroderma can be deep and functionally important, but systemic sclerosis is the branch associated with characteristic vascular disease and possible internal-organ involvement.
What Causes Scleroderma and How Is It Diagnosed?
Scleroderma does not have one proven universal cause, and diagnosis depends on combining the clinical pattern with targeted laboratory, vascular and organ assessment rather than relying on one test.
Is There One Known Cause of Scleroderma?
No; scleroderma appears to arise from interacting immune, vascular, fibrotic, genetic and environmental influences rather than from one infection, food or exposure.
Research supports a model in which susceptible tissue develops abnormal immune activation and vascular injury, which can stimulate prolonged fibroblast activity and excessive extracellular-matrix production. The exact initiating sequence varies and remains incompletely understood.
How Does a Doctor Diagnose Scleroderma?
Scleroderma diagnosis combines symptom history, skin examination, vascular findings, physical examination and targeted testing, followed by organ assessment when systemic sclerosis is suspected.
The clinician asks whether hard or tight skin fits localized disease or the distribution of systemic sclerosis, whether Raynaud or fingertip vascular injury is present, and whether symptoms point toward lung, gastrointestinal, heart or kidney involvement. No single laboratory or biopsy result replaces that clinical synthesis.
Which Blood Tests and Vascular Tests Can Support Diagnosis?
ANA and disease-associated autoantibodies can support systemic-sclerosis assessment, while nailfold capillaroscopy can identify characteristic small-vessel abnormalities in selected people with Raynaud symptoms.
A positive ANA is not enough to diagnose systemic sclerosis because antinuclear antibodies can occur in other autoimmune diseases and in some people without systemic sclerosis. Autoantibody pattern, symptoms, skin findings and vascular changes must be interpreted together.
What Conditions Can Resemble Scleroderma?
Other autoimmune and fibrosing disorders can produce overlapping skin, vascular or musculoskeletal findings, so an atypical hardening pattern deserves a controlled differential rather than automatic labeling as scleroderma.
Lupus erythematosus can overlap with systemic autoimmune symptoms and vascular complaints, but it has a different disease pattern and should remain a separate diagnostic pathway.
Dermatomyositis becomes a more relevant differential when characteristic skin findings occur together with prominent muscle weakness or other myositis features.
How Are Internal Organs Checked in Systemic Sclerosis?
Systemic-sclerosis assessment is directed toward organs known to be at risk, particularly the lungs, pulmonary circulation and heart, kidneys, and gastrointestinal tract.
Pulmonary function testing and chest imaging may be used to evaluate interstitial lung disease; echocardiography and other cardiopulmonary tests help assess pulmonary hypertension or heart involvement. Blood pressure and kidney function are monitored for renal complications, while reflux, swallowing difficulty and motility symptoms guide gastrointestinal evaluation.
Figure 3. Systemic sclerosis is not diagnosed from hard skin or one antibody alone. The clinical pattern, vascular findings and targeted tests establish the branch, after which organ assessment becomes part of the diagnostic task.
How Is Scleroderma Treated?
Scleroderma treatment is manifestation-specific, meaning skin fibrosis, vascular disease, digestive symptoms, lung disease and movement restriction may each require different therapies.
Can Scleroderma Be Completely Cured?
There is currently no single treatment that cures every form of scleroderma, so therapy focuses on controlling active disease, relieving symptoms, preserving function and preventing or limiting organ damage.
Some inflammatory or early fibrotic changes can improve, but established fibrosis is not guaranteed to reverse completely. Treatment expectations should therefore focus on measurable disease control and function rather than promising normal tissue restoration.
How Is Skin Thickening or Active Skin Disease Treated?
Active skin disease is treated according to the scleroderma branch: selected localized morphea may respond to topical therapy, phototherapy or systemic immune-directed treatment, while systemic-sclerosis skin fibrosis may require rheumatology-directed immunomodulatory therapy.
Current systemic-sclerosis recommendations include options such as methotrexate, mycophenolate mofetil or rituximab for selected skin fibrosis, with treatment chosen around disease activity, organ involvement, comorbidities and specialist judgment. This is not a “best scleroderma medicine” ranking.
How Are Raynaud Phenomenon and Finger Ulcers Treated?
Treatment of scleroderma-related vascular disease aims to reduce vasospasm, improve circulation, protect the fingers and promote healing of digital ulcers.
Cold protection and smoking avoidance are foundational, while vasodilator therapy or more intensive vascular treatment may be needed for frequent attacks, ulcers or threatened tissue. The medication pathway is individualized because severity and organ context differ between patients.
How Are Lung, Digestive, Heart or Kidney Complications Treated?
Internal-organ complications require organ-directed treatment rather than simply increasing therapy aimed at the skin.
Interstitial lung disease may require immune-directed and/or antifibrotic treatment, pulmonary arterial hypertension requires specialist pulmonary-vascular therapy, and gastrointestinal disease is treated according to reflux or motility problems. Scleroderma renal crisis is a medical emergency in which rapid recognition and immediate appropriate blood-pressure treatment are critical.
How Do Physical and Occupational Therapy Help?
Physical and occupational therapy can help preserve joint range of motion, hand function and daily activity when tightening skin or soft-tissue contracture limits movement.
Therapy may include clinician-directed stretching, hand exercises, positioning strategies and adaptive techniques for everyday tasks. The goal is to protect function while medical treatment addresses active disease.
Figure 4. Scleroderma treatment is organized by manifestation. Skin fibrosis, vasculopathy, lung disease, gastrointestinal problems, renal crisis and movement restriction do not share one universal treatment pathway.
How Can People With Scleroderma Protect Their Skin, Monitor the Disease, and Know When to Seek Urgent Care?
Daily skin protection, cold avoidance, movement exercises and long-term organ monitoring help reduce complications, while new breathing, kidney or severe circulation symptoms require prompt assessment.
How Can Moisturizing and Gentle Skin Care Help?
Scleroderma skin can become dry, tight and fragile, so regular moisturization and gentle cleansing can reduce cracking, irritation and discomfort; the broader dry skin page covers general xerosis care in more depth.
Harsh scrubbing and strongly drying products can worsen discomfort in already tight or fragile skin. Skin care supports comfort and barrier protection, but it does not replace disease-directed treatment for active fibrosis.
How Can Cold Protection Reduce Vascular Symptoms?
Keeping the whole body and extremities warm can reduce cold-triggered Raynaud attacks and help protect already vulnerable finger circulation.
Layers, gloves, warm footwear and avoiding abrupt cold exposure are practical measures. Protecting the hands when handling frozen items also reduces sudden local cooling that can provoke vasospasm.
Why Are Stretching and Joint Movement Important?
Regular clinician-directed stretching and movement help preserve mobility as tightening skin and soft tissue increase the risk of stiffness and contracture.
Exercises should match the person’s limitations and disease activity. The aim is consistent preservation of range rather than forceful stretching through painful or injured tissue.
Why Does Systemic Sclerosis Require Long-Term Organ Monitoring?
Systemic sclerosis requires ongoing follow-up because skin appearance does not reliably reveal what is happening in the lungs, kidneys, heart or digestive tract.
Organ disease can emerge or progress on a timeline that differs from the visible skin course. Follow-up commonly combines symptom review with blood pressure, kidney assessment, pulmonary function testing and cardiopulmonary evaluation according to individual risk and prior findings.
Which Scleroderma Symptoms Need Prompt or Urgent Medical Care?
New or rapidly worsening shortness of breath, chest pain, a sudden major rise in blood pressure, symptoms of acute kidney dysfunction or severely painful discolored fingers require prompt medical assessment.
Progressive skin tightening, new fingertip ulcers, worsening swallowing difficulty or reflux, declining exercise tolerance and increasing movement restriction also deserve timely review rather than waiting for the next routine visit.
Severe prolonged digital ischemia can threaten tissue viability and, if tissue death develops, enters a separate gangrene pathway; persistent severe finger pain and discoloration should not be dismissed as an ordinary Raynaud episode.
What Should You Remember About Scleroderma?
Scleroderma is an umbrella term for fibrosing disorders, and the most important clinical distinction is whether disease remains localized to the skin and nearby tissues or represents systemic sclerosis with vascular and internal-organ risk.
- Excess collagen and fibrosis make affected tissue hard, thick and less flexible.
- Localized scleroderma and systemic sclerosis are related terms but not interchangeable disease categories.
- Localized disease can extend deeply into nearby tissues without producing the systemic-sclerosis internal-organ pattern.
- Systemic sclerosis combines autoimmunity, vasculopathy and fibrosis.
- Limited cutaneous disease describes skin distribution; it does not mean internal-organ complications are impossible.
- Puffy fingers, sclerodactyly, telangiectasia, calcinosis and Raynaud phenomenon can be useful clinical clues.
- Raynaud may precede other systemic-sclerosis findings, but Raynaud alone is not diagnostic.
- The exact cause is uncertain and likely reflects interacting immune, vascular, genetic and environmental factors.
- No single antibody or laboratory test establishes systemic sclerosis by itself.
- Nailfold capillaroscopy can help evaluate small-vessel changes when Raynaud and secondary disease are suspected.
- Systemic sclerosis requires assessment of lungs, pulmonary circulation and heart, kidneys and gastrointestinal tract.
- Treatment is manifestation-specific rather than one universal scleroderma regimen.
- Skin-directed, vascular, pulmonary, gastrointestinal and renal treatments solve different clinical problems.
- Physical and occupational therapy help preserve movement and daily function.
- Gentle moisturization and cold protection support comfort and circulation.
- Stable-looking skin does not guarantee stable internal organs.
- Scleroderma renal crisis and threatened digital tissue are urgent complications.
- There is no single universal cure, but early treatment and ongoing monitoring can reduce symptoms and limit damage.
Core pathway: Recognize fibrosis → classify localized vs systemic disease → assess vascular and organ risk → treat the active manifestation → protect skin and function → continue long-term monitoring.
Frequently Asked Questions About Scleroderma
The main scleroderma questions concern terminology, autoimmune disease, reversibility of skin hardening, internal-organ involvement and cure.
Is Scleroderma the Same as Systemic Sclerosis?
No. Scleroderma is a broader umbrella term that includes localized forms such as morphea as well as systemic sclerosis. Using the terms as perfect synonyms can hide the important localized-versus-systemic distinction.
Is Scleroderma an Autoimmune Disease?
Systemic sclerosis is an autoimmune connective-tissue disease involving immune dysfunction, vascular abnormalities and fibrosis. Localized scleroderma is also an inflammatory fibrosing disorder but does not have the same systemic vascular and internal-organ pattern.
Can Hardened Skin From Scleroderma Become Soft Again?
Some active or early skin changes may soften with time and treatment, but established fibrosis is not guaranteed to return completely to normal skin. Improvement depends on disease type, activity, depth and treatment response.
Can Scleroderma Affect Internal Organs?
Systemic sclerosis can affect the lungs, digestive tract, heart, kidneys and blood vessels in addition to the skin. Localized scleroderma does not produce this characteristic systemic organ pattern.
Is There a Cure for Scleroderma?
There is currently no single cure for scleroderma, but treatment can control specific manifestations, preserve function and reduce complications. Systemic disease also requires long-term monitoring because internal-organ risk can evolve separately from the skin.
Sources & Evidence
NIAMS — Scleroderma Overview, Symptoms & Causes — Used for the localized-versus-systemic hierarchy, autoimmune/vascular/fibroblast mechanism, limited-versus-diffuse skin distribution, internal-organ risk and no-cure framing.
NIAMS — Diagnosis, Treatment, and Steps to Take — Used for the no-single-test principle, antibody interpretation, lung/heart/kidney assessment, manifestation-specific treatment, physical/occupational therapy, renal-crisis risk and long-term monitoring.
DermNet — Morphoea (Localized Scleroderma) — Used for the fact that morphea can extend into fat, fascia, muscle or bone while remaining distinct from systemic sclerosis and its internal-organ vasculopathy.
American Academy of Dermatology — Scleroderma Overview — Used for skin hardening, localized/systemic disease framing and clinical skin manifestations.
American Academy of Dermatology — Scleroderma Self-Care — Used for moisturization, gentle cleansing, movement exercises, warmth and skin protection.
EULAR Recommendations for the Treatment of Systemic Sclerosis: 2023 Update — Used to audit current manifestation-specific systemic-sclerosis therapy, including skin fibrosis, Raynaud/digital ulcers, pulmonary arterial hypertension, renal crisis, interstitial lung disease and gastrointestinal disease.
